How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/febrile-neutropenia-caused-by-myelosuppressive-anti-cancer-drugs.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Febrile neutropenia caused by myelosuppressive anti-cancer drugs — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Febrile neutropenia caused by myelosuppressive anti-cancer drugs (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Febrile neutropenia caused by myelosuppressive anti-cancer drugs, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Rolvedon	EFLAPEGRASTIM	Spectrum Pharms	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor		2022-01-01
ROLVEDON	EFLAPEGRASTIM-XNST	SPECTRUM PHARMS	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

SPECTRUM PHARMS · 1 drug in Febrile neutropenia caused by myelosuppressive anti-cancer drugs
Spectrum Pharms · 1 drug in Febrile neutropenia caused by myelosuppressive anti-cancer drugs

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Febrile neutropenia caused by myelosuppressive anti-cancer drugs:

Cite this brief

Drug Landscape (2026). Febrile neutropenia caused by myelosuppressive anti-cancer drugs — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/febrile-neutropenia-caused-by-myelosuppressive-anti-cancer-drugs. Accessed 2026-06-10.

Febrile neutropenia caused by myelosuppressive anti-cancer drugs full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing